Novartis, CH0012005267

Novartis stock: UBS keeps CHF 116 target and Neutral rating

Published on 10/23/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 sales hit USD 14.41 billion, up 3.00 percent. Novartis stock costs EUR 139.18 on October 23, 2026, minus 0.29 percent versus Xetra close.

Analyst rating stays Neutral

UBS maintained its Neutral rating and CHF 116.00 target on October 19, 2026.
Novartis reported USD 14.41 billion in second-quarter sales, up 3.00 percent year over year.
Novartis stock cost EUR 139.18 at Lang & Schwarz on October 23, 2026 at 3:16 p.m. CEST, minus 0.29 percent versus the Xetra close.
Novartis is scheduled to publish third-quarter results on October 27, 2026.

Pop-Art-Illustration einer DNA-Doppelhelix mit Kapsel in leuchtendem Halftone-Raster — Novartis AG CH0012005267 – Pop-Art-Comic mit stilisierter DNA-Helix und Kapsel im bunten Halftone-Raster, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) has a CHF 116.00 price target from UBS, which kept its Neutral rating on October 19, 2026, according to DER AKTIONÄR. The target is 10.66 percent below the CHF 128.36 SIX quote on October 23, 2026 at 3:11 p.m. CEST. At Lang & Schwarz, the stock stood at EUR 139.18 on October 23, 2026 at 3:16 p.m. CEST, down EUR 0.40 or 0.29 percent versus the Xetra close of October 22, 2026 at EUR 139.58.

Second-quarter sales rose 3.00 percent

Novartis reported USD 14.41 billion in second-quarter 2026 sales, up 3.00 percent from USD 14.05 billion a year earlier. Operating income reached USD 4.75 billion, while net income fell 19.00 percent to USD 3.26 billion. Core operating income was USD 5.94 billion, flat year over year, with a 41.20 percent core margin versus 42.20 percent in the second quarter of 2025, according to Ticker Scout.

Stock stays below the 52-week high

The SIX quote placed Novartis at CHF 128.36 on October 23, 2026 at 3:11 p.m. CEST, within a 52-week range of CHF 97.05 to CHF 132.68. The price was 3.26 percent below the high and 32.26 percent above the low. Trading volume stood at 1,202,069 shares at that timestamp.

Valuation and reporting date

Novartis carried a price-to-earnings ratio of 23.82 and a market capitalization of CHF 244.0 billion on October 23, 2026. The company is scheduled to publish third-quarter 2026 results on October 27, 2026, according to its investor calendar.

What does the target imply?

UBS places its CHF 116.00 target below the latest SIX quote, while the second-quarter figures combine sales growth with lower reported earnings. The October 27 results will provide the next period-specific test of sales, margin and profit trends.

EUR 139.18 after the Xetra close

At Lang & Schwarz, Novartis stood at EUR 139.18 on October 23, 2026 at 3:16 p.m. CEST, down EUR 0.40 or 0.29 percent versus the Xetra close of October 22, 2026 at EUR 139.58.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.